Skip to content
← Full study record

NCT04971226 · MORE INFO

Limitations, agreements, and source contact

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP · Source last updated 2026-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in clinical trial or disclosure of trial results in their entirety.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
Adverse Events data were not collected from the 4 participants who are not included in the Safety Set as they did not receive any treatment.
point Of Contact
email
novartis.email@novartis.com
organization
Novartis Pharmaceuticals
phone
862-778-3000
title
Clinical Disclosure Office
Complete source fields
certain Agreement
other Details
The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in clinical trial or disclosure of trial results in their entirety.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
Adverse Events data were not collected from the 4 participants who are not included in the Safety Set as they did not receive any treatment.
point Of Contact
email
novartis.email@novartis.com
organization
Novartis Pharmaceuticals
phone
862-778-3000
title
Clinical Disclosure Office

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice